Skip to main content

Table 3 Review of the main clinical trials performed in first line metastatic colorectal cancer

From: Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

  Chemotherapy Liver metastases only (%) One metastatic site only (%) ORR (%) mPFS (months) mOS (months) Ref Comments
Tournigand C et al. [9] FOLFIRI NR 56 56 8.5 21.5 J Clin Oncol 2004; 22(2):229–37.  
Colluci G et al. [34] FOLFIRI 50 56 31 7 14 J Clin Oncol 2005; 23:4866–4875.  
Labiancha R et al. [35] FOLFIRI NR NR 42 6 18 Annals of Oncology 2011; 22:1236–1242.  
Koopman M (CAIRO study) [36] FOLFOX or FOLFIRI 23 NR 41 7,8 17.4 Lancet 2007; 370:135–42.  
Ducreux M (FFCD2000-05) [37] FOLFOX NR 52 58 7.6 16.2 Lancet Oncol 2011; 12:1032–44.  
Chibaudel B (OPTIMOX2 study) [25] FOLFOX7 NR 42 59.6 8,6 23.8 J Clin Oncol 2009; 27:5727–5733. Maintenance arm
Maughan TS (COIN study arm 1) [38] FOLFOX 21 35 57 8,6 17.9 Lancet 2011; 377(9783):2103–2114.  
Hurwitz H et al. [13] IFL + Bev NR 37 44.8 10.6 20.3 N Engl J Med 2004; 350:2335–42.  
Fuchs CS (BICC study) [23] Folfiri-bev NR NR 57.9 11.2 28 J Clin Oncol 2007; 25:4779–4786.  
SALTZ LB (NO16966) [39] FOLFOX + bev NR 43   9.4 21.3 J Clin Oncol. 2008; 26(12):2013–9.  
Schmoll HJ (Horizon study) [40] FOLFOX + bev 22 45 47 10.3 22.3 J Clin Oncol 2012; 30:3588–3595.  
Van Cutsem(Crystal study) [41] FOLFIRI cetux 21,5 NR 57,2 9.9 23.5 J Clin Oncol 2011; 29:2011–2019. Kras wt only
Maughan TS (COIN study arm 2) [38] FOLFOX cetux 24 37 64 8.6 17 Lancet. 2011; 377(9783):2103–2114. Kras wt only
Douillard JY (Prime study) [42] FOLFOX pamitumumab 18 21 55 9.6 23.9 J Clin Oncol 2010; 28:4697–4705. Kras wt only
Bokemeyer (OPUS study) [43] FOLFOX + cetux 30 44 58 8.3 22.8 Annals of Oncology 2011; 22:1535–1546. Kras wt only
Masi G [44] FOLFOXIRI 34 55 60 9.8 23.4 J Natl Cancer Inst 2011;103:21–30.  
Masi G [30] FOLFOXIRI beva 53 58 77 13.1 30.9 Lancet Oncol 2010; 11:845–52.  
  1. (NR: not reported).